NCT01866033 - A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Healthy Volunteer

Interventions

DRUG

PCI-32765 (Treatment A)

560 mg capsules administered by mouth on Day 1, Period 1

DRUG

PCI-32765 (Treatment B)

560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule

DRUG

PCI-32765 (Treatment C)

140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule

DRUG

13C6 PCI-32765 (reference)

100 mcg administered intravenously 2 h after study drug

Trial Locations (1)

Merksem